ABBV Stock Analysis: Buy, Sell, or Hold?
ABBV - ABBVIE INC.
$223.43
4.41 (2.01%)
ā²
5d:
+0.19%
30d:
-4.28%
90d:
+3.07%
BUY
HIGH Confidence
Analysis Updated: Feb 6, 2026 12:00 AM ET
Earnings: Apr 23, 2026
Smart Money Accumulation
ABBV is down 3.7% this week, but smart money is accumulating calls. Top strike: $250 2026-03-20 with 7,487 OI. Call ratio: 60% View Scanner →
Strength: 2.9/10
Get Alerted When ABBV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called ABBV this week
71% bullish • 2 bearish
71% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ā BUY SIGNAL: ABBV trading at deep discount. Market pricing in -3.5% annual earnings decline, creating value opportunity for patient investors.
ā BUY SIGNAL: ABBV trading at deep discount. Market pricing in -3.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$348.26
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$216.24
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABBV is currently trading at $223.43, which is considered fair relative to its 30-day fair value range of $217.21 to $227.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.1) compared to its historical average (15.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $229.78. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $229.78. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$217.21 -
$227.01
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($244.93)
Fair Price Analysis
30-Day Fair Range
$217.21 -
$227.01
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$204.27
Resistance Level
$229.79
Current Trend
Strong Uptrend
Technical data as of
Feb 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.05
Wall Street Target
$244.93
(+9.6%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
-88.7%
Profit Margin
6.9%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
14.1 vs 15.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$215.61
(-4%)
2-Year Target
$208.06
(-7%)
3-Year Target
$200.78
(-10%)
3-Yr Target (if PE normalizes)
(PE: 14ā16)
$224.38
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 9.8%)
$469.61
(+110%)
Base:
(SPY PE: 14.0, Growth: 9.8%)
$295.85
(+32%)
Bear:
(PE: 11.9, Growth: 9.8%)
$251.47
(+13%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Forward PE: 15.46 | Forward EPS (Implied): $14.46
Bull Case
$269.79
(+21%)
Analyst growth 15.0%, PE expands to 16.2
Base Case
$223.43
(0%)
Market implied 0.0%, PE stable at 15.5
Bear Case
$170.92
(-24%)
Severe decline -15.0%, PE contracts to 13.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
š”
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.0 to 15.7
Stabilization Target:
$249.70
(+11.8%)
PE Expansion Potential:
+11.8%
Share & Embed Analysis
Last updated: February 08, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABBV showing a specific setup today?
Insider Activity (6 Months)
1
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Julie Johnson
SELL
2025-12-18
Julia Letlow
SELL
2025-12-08
Julie Johnson
SELL
2025-11-13
Featured in Portfolios
ABBV is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$139 | 67 BUY |
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1186 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$342 | 66 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$200 | 59 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$121 | 64 BUY |
Advanced ABBV Option Strategies
Professional options setups generated by AI based on today's ABBV price and gamma walls.
